Key Market Insights

• With six approved therapies and over 970 preclinical / clinical product candidates, CAR-T cell therapies represent the most active segment of the pharmaceutical domain
• More than 80% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; CD19 and BCMA have emerged as the most popular target antigens
• Several scientists from renowned universities are presently involved in clinical development efforts of CAR-T cell therapies; these KOLs are primarily based in the US and China
• Specifically, for CAR-T cell therapies, extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors
• In the last 10 years, over 750 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of therapies
• Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development
• A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021
• Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested USD 25 billion, across 260+ instances, during the period 2000-2022
• More than 6,500 patents have been granted / filed for CAR-T cell therapies, primarily led by the non-industry players
• With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade
• The projected opportunity within the CAR-T cell therapies market is expected to be well distributed across key / emerging players and different geographical regions

Table of Contents

1. . PREFACE    

1.1.                  Scope of the Report

1.2.                  Market Segmentations

1.3.                  Research Methodology

1.4.                  Key Questions Answered

1.5.                  Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1.                  Chapter Overview

3.2.                  Pillars of Cancer Therapy

3.3.                  Overview of Immunotherapies

3.4.                  Fundamentals of Cancer Immunotherapy

3.5.                  Classification of Cancer Immunotherapy

3.5.1.               By Mechanism of Action

3.5.1.1.            Active Immunotherapy

3.5.1.2.            Passive Immunotherapy

3.5.2.               By Type of Target

3.5.3.               By Approach

3.5.3.1.            Activation and Suppression Immunotherapy

3.5.4.               By Product Class

3.5.4.1.            Monoclonal Antibodies

3.5.4.2.            Bispecific Antibodies

3.5.4.3.            Cytokines

3.5.4.4.            Oncolytic Virus Therapy

3.5.4.5.            Therapeutic Cancer Vaccines

3.5.4.6.            Cell-based Therapies

3.6.                  T-Cell Immunotherapies

3.6.1.               Historical Evolution

3.6.2.               Key Considerations for Developing T-Cell Immunotherapies

3.6.3.               Strategies Employed for the Redirection of T-Cells

3.6.4.               Manufacturing of Engineered T-Cells

3.6.5.               T-Cell Transduction and Transfection Methods

3.6.5.1.            Retroviral Vectors

3.6.5.2.            Lentiviral Vectors

3.6.5.3.            Non-viral Transfection Methods

3.7.                  Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

3.7.1.               Development History

3.7.2.               Anatomical Layout of CAR

3.7.2.1.            Ectodomain

3.7.2.2.            Transmembrane (TM) Domain

3.7.2.3.            Endodomain

3.7.3.               Development of CAR-T Cells

3.7.4.               Universal CAR-T Cells

3.7.5.               Route of Administration

3.7.6.               Case Study on CD19 CAR-T Cell Therapies

3.7.6.1.            Other Important Biological Targets for CAR Development

3.7.7.               Challenges Associated with CAR-T Cell Therapies

3.7.7.1.            Competitive Risks

3.7.7.2.            Clinical Risks

3.7.7.3.            Regulatory Risks

3.7.7.4.            Commercial Risks

3.8.                  Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  CAR-T Cell Therapies: Overall Market Landscape

4.2.1.               Analysis by Type of Developer

4.2.2.               Analysis by Phase of Development

4.2.3.               Analysis by Therapeutic Area

4.2.4.               Analysis by Phase of Development and Therapeutic Area

4.2.5.               Analysis by Key Target Indication

4.2.6.               Analysis by Key Target Antigen

4.2.7.               Analysis by Source of T-Cells

4.2.8.               Analysis by Phase of Development and Source of T-Cells

4.2.9.               Analysis by Route of Administration

4.2.10.             Analysis by Dosing Frequency

4.2.11.             Analysis by Target Patient Segment

4.2.12.             Analysis by Type of Therapy

4.2.13.             Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies

4.2.14.             Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies

4.3.                  CAR-T Cell Therapies: Overall Developer Landscape

4.3.1.               Analysis by Year of Establishment

4.3.2.               Analysis by Company Size

4.3.3.               Analysis by Location of Headquarters

5. KEY INSIGHTS

5.1.                  Chapter Overview

5.2.                  CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens

5.2.1.               Popular Targets Related to Hematological Malignancies

5.2.2.               Popular Targets Related to Solid Tumors

5.3.                  CAR-T Cell Immunotherapies: CAR Construct Analysis

5.3.1.               Analysis by Generation of CAR

5.3.2.               Analysis by Type of scFv Antibody

5.3.3.               Analysis by Type of Virus Used

5.3.4.               Analysis by Type of Gene Transfer Method Used

5.3.5.               Analysis by Type of Co-Stimulatory Domain

6. CLINICAL TRIAL ANALYSIS

6.1.                  Chapter Overview

6.2.                  Scope and Methodology

6.3.                  CAR-T Cell Therapies: Clinical Trial Analysis

6.3.1.               Analysis of Trials by Trial Registration Year

6.3.2.               Analysis of Enrolled Patient Population by Trial Registration Year

6.3.3.               Analysis by Trial Status

6.3.4.               Analysis by Trial Registration Year and Trial Status

6.3.5.               Analysis by Trial Phase

6.3.6.               Analysis of Enrolled Patient Population by Trial Phase

6.3.7.               Analysis by Target Patient Segment

6.3.8.               Analysis by Type of Sponsor / Collaborator

6.3.9.               Analysis by Study Design

6.3.10.             Most Active Industry Players: Analysis by Number of Registered Trials

6.3.11.             Most Active Non-Industry Players: Analysis by Number of Registered Trials

6.3.12.             Analysis by Key Focus Areas

6.3.13.             Analysis of Trials by Geography

6.3.14.             Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS

7.1.                  Chapter Overview

7.2.                  Assumptions and Key Parameters

7.3.                  Methodology

7.4.                  CAR-T Cell Therapies: Key Opinion Leaders

7.4.1.               Analysis by Type of Organization

7.4.2.               Analysis by Affiliated Organization

7.4.3.               Analysis by Qualification

7.4.4.               Analysis by Geographical Location of KOLs

7.4.5.               KOL Activeness versus KOL Strength

7.4.6.               Most Prominent KOLs: Analysis by RA score

7.4.7.               Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. CAR-T CELL THERAPY PROFILES

8.1.                  Chapter Overview

8.2.                  Kymriah® / Tisagenlecleucel / CTL019 (Novartis)

8.2.1.               Therapy Overview

8.2.2.               Clinical Trial Information

8.2.3.               Clinical Trial Endpoints

8.2.4.               Clinical Trial Results

8.2.5.               Estimated Sales Revenues

8.3.                  Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)

8.3.1.               Therapy Overview

8.3.2.               Clinical Trial Information

8.3.3.               Clinical Trial Endpoints

8.3.4.               Clinical Trial Results

8.3.5.               Estimated Sales Revenues

8.4.                  Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences)

8.4.1.               Therapy Overview

8.4.2.               Clinical Trial Information

8.4.3.               Clinical Trial Endpoints

8.4.4.               Clinical Trial Results

8.4.5.               Estimated Sales Revenues

8.5.                  Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)

8.5.1.               Therapy Overview

8.5.2.               Clinical Trial Information

8.5.3.               Clinical Trial Endpoints

8.5.4.               Clinical Trial Results

8.5.5.               Estimated Sales Revenues

8.6.                  Abecma™ / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)

8.6.1.               Therapy Overview

8.6.2.               Clinical Trial Information

8.6.3.               Clinical Trial Endpoints

8.6.4.               Clinical Trial Results

8.6.5.               Estimated Sales Revenues

8.7.                  Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)

8.7.1.               Therapy Overview

8.7.2.               Clinical Trial Information

8.7.3.               Clinical Trial Endpoints

8.7.4.               Clinical Trial Results

8.7.5.               Estimated Sales Revenues

8.8.                  Carteyva™ / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)

8.8.1.               Therapy Overview

8.8.2.               Clinical Trial Information

8.8.3.               Clinical Trial Endpoints

8.8.4.               Clinical Trial Results

8.8.5.               Estimated Sales Revenues

8.9.                  TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)

8.9.1.               Therapy Overview

8.9.2.               Clinical Trial Information

8.9.3.               Clinical Trial Endpoints

8.10.                AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)

8.10.1.             Therapy Overview

8.10.2.             Clinical Trial Information

8.10.3.             Clinical Trial Endpoints

8.10.4.             Clinical Trial Results

8.10.5.             Estimated Sales Revenues

8.11.                AUTO3 / CD19/22 CAR-T (Autolus)

8.11.1.             Therapy Overview

8.11.2.             Clinical Trial Information

8.11.3.             Clinical Trial Endpoints

8.11.4.             Clinical Trial Results

8.11.5.             Estimated Sales Revenues

9. PARTNERSHIPS AND COLLABORATIONS

9.1.                  Chapter Overview

9.2.                  Partnership Models

9.3.                  CAR-T Cell Therapies: Partnerships and Collaborations

9.3.1.               Analysis by Year of Partnership

9.3.2.               Analysis by Type of Partnership

9.3.3.               Analysis by Year of Partnership and Type of Partnership

9.3.4.               Analysis by Type of Partner

9.3.5.               Most Popular Products: Analysis by Number of Partnerships

9.3.6.               Most Active Industry Players: Analysis by Number of Partnerships

9.3.7.               Most Active Non-Industry Players: Analysis by Number of Partnerships

9.3.8.               Analysis by Geography

9.3.8.1.            Intercontinental and Intracontinental Deals

9.3.8.2.            International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS

10.1.                Chapter Overview

10.2.                Types of Funding

10.3.                CAR-T Cell Therapies: Funding and Investment Analysis

10.3.1.             Analysis of Instances by Year

10.3.2.             Analysis of Amount Invested by Year

10.3.3.             Analysis by Type of Funding

10.3.4.             Analysis by Type of Investor

10.3.5.             Most Active Players: Analysis by Number of Instances

10.3.6.             Most Active Investors: Analysis by Amount Invested

10.3.7.             Analysis of Amount Invested by Geography

10.3.8.             Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS

11.1.                Chapter Overview

11.2.                Scope and Methodology

11.3.                CAR-T Cell Therapies: Patent Analysis

11.3.1.             Analysis by Patent Publication Year

11.3.2.             Analysis by Patent Application Year

11.3.3.             Analysis by Geography

11.3.4.             Analysis by Type of Player

11.3.5.             Analysis by CPC Symbols

11.3.6.             Analysis by Key Focus Area

11.3.7.             Leading Players: Analysis by Number of Patents

11.3.8.             CAR-T Cell Therapies: Patent Benchmarking

11.3.9.             Analysis By Patent Characteristics

11.3.10.           CAR-T Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING

12.1.                Chapter Overview

12.2.                Overview of Cell Therapy Manufacturing

12.3.                Cell Therapy Manufacturing Models

12.3.1.             Centralized Manufacturing Model

12.3.2.             Decentralized Manufacturing Model

12.4.                Scalability of Cell Therapy Manufacturing Processes

12.4.1.             Scale-Up

12.4.2.             Scale-Out

12.5.                Types of Cell Therapy Manufacturers

12.6.                Key Challenges Related to Manufacturing of Cell Therapies

12.7.                Key Considerations for Cell Therapy Manufacturing

12.7.1.             Characterization

12.7.2.             Cost of Goods

12.8.                Automation of Cell Therapy Manufacturing Process

12.9.                Cell Therapy Manufacturing Supply Chain

12.10.              Comparison of Players Having In-House Capabilities and Contract Manufacturers

12.11.              Regulatory Landscape

12.12.              Future Perspectives

13. COST PRICE ANALYSIS

13.1.                Chapter Overview

13.2.                Factors Contributing to the High Price of Cell / Gene Therapies

13.3.                Pricing Models for T-Cell Immunotherapies

13.3.1.             Based on Associated Costs

13.3.2.             Based on Availability of Competing Products

13.3.3.             Based on Patient Segment

13.3.4.             Based on Opinions of Industry Experts

13.4.                Reimbursement related Considerations for T-cell Immunotherapies

13.4.1.             Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14.1.                Chapter Overview

14.2.                Scope and Limitations

14.3.                Key Assumptions and Forecast Methodology

14.4.                Global CAR-T Cell Therapies Market, 2022-2035

14.4.1.             CAR-T Cell Therapies Market: Analysis by Target Indication

14.4.2.             CAR-T Cell Therapies Market: Analysis by Target Antigen

14.4.3.             CAR-T Cell Therapies Market: Analysis by Key Players

14.4.4.             CAR-T Cell Therapies Market: Analysis by Geography

14.4.5.             Product Wise Sales Forecast

14.4.5.1.          Kymriah® / Tisagenlecleucel / CTL019 (Novartis)

14.4.5.1.1.                   Sales Forecast (USD Million)

14.4.5.1.2.                   Net Present Value

14.4.5.1.3.                   Value Creation Analysis

14.4.5.2.          Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)

14.4.5.2.1.                   Sales Forecast (USD Million)

14.4.5.2.2.                   Net Present Value (USD Million)

14.4.5.2.3.                   Value Creation Analysis

14.4.5.3.          Tecartus™:  / Brexucabtagene Autoleucel (Gilead Sciences)

14.4.5.3.1.                   Sales Forecast (USD Million)

14.4.5.3.2.                   Net Present Value (USD Million)

14.4.5.3.3.                   Value Creation Analysis

14.4.5.4.          Abecma™:  / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)

14.4.5.4.1.                   Sales Forecast (USD Million)

14.4.5.4.2.                   Net Present Value (USD Million)

14.4.5.4.3.                   Value Creation Analysis

14.4.5.5.          Carvykti™:  / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)

14.4.5.5.1.                   Sales Forecast (USD Million)

14.4.5.5.2.                   Net Present Value (USD Million)

14.4.5.5.3.                   Value Creation Analysis

14.4.5.6.          Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)

14.4.5.6.1.                   Sales Forecast (USD Million)

14.4.5.6.2.                   Net Present Value (USD Million)

14.4.5.6.3.                   Value Creation Analysis

14.4.5.7.          Carteyva™:  / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)

14.4.5.7.1.                   Sales Forecast (USD Million)

14.4.5.7.2.                   Net Present Value (USD Million)

14.4.5.7.3.                   Value Creation Analysis

14.4.5.8.          BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)

14.4.5.8.1.                   Sales Forecast (USD Million)

14.4.5.8.2.                   Net Present Value (USD Million)

14.4.5.8.3.                   Value Creation Analysis

14.4.5.9.          CD19 CAR-T (Wuhan Si'an Medical Technology)

14.4.5.9.1.                   Sales Forecast (USD Million)

14.4.5.9.2.                   Net Present Value (USD Million)

14.4.5.9.3.                   Value Creation Analysis

14.4.5.10.        Descartes-11 (Cartesian Therapeutics)

14.4.5.10.1.     Sales Forecast (USD Million)

14.4.5.10.2.     Net Present Value (USD Million)

14.4.5.10.3.     Value Creation Analysis

14.4.5.11.        Descartes-08 (Cartesian Therapeutics)

14.4.5.11.1.     Sales Forecast (USD Million)

14.4.5.11.2.     Net Present Value (USD Million)

14.4.5.11.3.     Value Creation Analysis

14.4.5.12.        Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)

14.4.5.12.1.     Sales Forecast (USD Million)

14.4.5.12.2.     Net Present Value (USD Million)

14.4.5.12.3.     Value Creation Analysis

14.4.5.13.        CNCT19 / HY001 (Juventas Cell Therapy)

14.4.5.13.1.     Sales Forecast (USD Million)

14.4.5.13.2.     Net Present Value (USD Million)

14.4.5.13.3.     Value Creation Analysis

14.4.5.14.        CD30.CAR-T / TT11 (Tessa Therapeutics)

14.4.5.14.1.     Sales Forecast (USD Million)

14.4.5.14.2.     Net Present Value (USD Million)

14.4.5.14.3.     Value Creation Analysis

14.4.5.15.        TAK-007 (Takeda)

14.4.5.15.1.     Sales Forecast (USD Million)

14.4.5.15.2.     Net Present Value (USD Million)

14.4.5.15.3.     Value Creation Analysis

14.4.5.16.        AUTO1 (Autolus)

14.4.5.16.1.     Sales Forecast (USD Million)

14.4.5.16.2.     Net Present Value (USD Million)

14.4.5.16.3.     Value Creation Analysis

14.4.5.17.        AUTO3 (Autolus)

14.4.5.17.1.     Sales Forecast (USD Million)

14.4.5.17.2.     Net Present Value (USD Million)

14.4.5.17.3.     Value Creation Analysis

14.4.5.18.        CD19 CAR-T (Bioray Laboratories)

14.4.5.18.1.     Sales Forecast (USD Million)

14.4.5.18.2.     Net Present Value (USD Million)

14.4.5.18.3.     Value Creation Analysis

14.4.5.19.        Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)

14.4.5.19.1.     Sales Forecast (USD Million)

14.4.5.19.2.     Net Present Value (USD Million)

14.4.5.19.3.     Value Creation Analysis

14.4.5.20.        IM19 CAR-T (Beijing Immunochina Medical Science Technology)

14.4.5.20.1.     Sales Forecast (USD Million)

14.4.5.20.2.     Net Present Value (USD Million)

14.4.5.20.3.     Value Creation Analysis

14.4.5.21.        CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)

14.4.5.21.1.     Sales Forecast (USD Million)

14.4.5.21.2.     Net Present Value (USD Million)

14.4.5.21.3.     Value Creation Analysis

14.4.5.22.        BinD19 (Shenzhen BinDeBio)

14.4.5.22.1.     Sales Forecast (USD Million)

14.4.5.22.2.     Net Present Value (USD Million)

14.4.5.22.3.     Value Creation Analysis

14.4.5.23.        CARCIK-CD19 (CoImmune)

14.4.5.23.1.     Sales Forecast (USD Million)

14.4.5.23.2.     Net Present Value (USD Million)

14.4.5.23.3.     Value Creation Analysis

14.4.5.24.        PBCAR269A (Precision BioSciences / Servier)

14.4.5.24.1.     Sales Forecast (USD Million)

14.4.5.24.2.     Net Present Value (USD Million)

14.4.5.24.3.     Value Creation Analysis

14.4.5.25.        CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)

14.4.5.25.1.     Sales Forecast (USD Million)

14.4.5.25.2.     Net Present Value (USD Million)

14.4.5.25.3.     Value Creation Analysis

14.4.5.26.        BCMA CAR-T (Chongqing Precision Biotech)

14.4.5.26.1.     Sales Forecast (USD Million)

14.4.5.26.2.     Net Present Value (USD Million)

14.4.5.26.3.     Value Creation Analysis

14.4.5.27.        CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)

14.4.5.27.1.     Sales Forecast (USD Million)

14.4.5.27.2.     Net Present Value (USD Million)

14.4.5.27.3.     Value Creation Analysis

14.4.5.28.        GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)

14.4.5.28.1.     Sales Forecast (USD Million)

14.4.5.28.2.     Net Present Value (USD Million)

14.4.5.28.3.     Value Creation Analysis

14.4.5.29.        iC9-CAR19 T cells (Bellicum Pharmaceuticals)

14.4.5.29.1.     Sales Forecast (USD Million)

14.4.5.29.2.     Net Present Value (USD Million)

14.4.5.29.3.     Value Creation Analysis

14.4.5.30.        ALLO-501A / ALLO-501 (Allogene Therapeutics)

14.4.5.30.1.     Sales Forecast (USD Million)

14.4.5.30.2.     Net Present Value (USD Million)

14.4.5.30.3.     Value Creation Analysis

14.4.5.31.        CD19/CD20-CAR-T (Yake Biotechnology)

14.4.5.31.1.     Sales Forecast (USD Million)

14.4.5.31.2.     Net Present Value (USD Million)

14.4.5.31.3.     Value Creation Analysis

14.4.5.32.        CD7 CAR-T (PersonGen BioTherapeutics)

14.4.5.32.1.     Sales Forecast (USD Million)

14.4.5.32.2.     Net Present Value (USD Million)

14.4.5.32.3.     Value Creation Analysis

14.4.5.33.        Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)

14.4.5.33.1.     Sales Forecast (USD Million)

14.4.5.33.2.     Net Present Value (USD Million)

14.4.5.33.3.     Value Creation Analysis

14.4.5.34.        CT053 (CARsgen Therapeutics)

14.4.5.34.1.     Sales Forecast (USD Million)

14.4.5.34.2.     Net Present Value (USD Million)

14.4.5.34.3.     Value Creation Analysis

14.4.5.35.        Anti-ALPP CAR-T Cells (TCRCure Biopharma)

14.4.5.35.1.     Sales Forecast (USD Million)

14.4.5.35.2.     Net Present Value (USD Million)

14.4.5.35.3.     Value Creation Analysis

14.4.5.36.        BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)

14.4.5.36.1.     Sales Forecast (USD Million)

14.4.5.36.2.     Net Present Value (USD Million)

14.4.5.36.3.     Value Creation Analysis

14.4.5.37.        ALLO-605 (Allogene Therapeutics)

14.4.5.37.1.     Sales Forecast (USD Million)

14.4.5.37.2.     Net Present Value (USD Million)

14.4.5.37.3.     Value Creation Analysis

14.4.5.38.        WU CART 007 (Wugen)

14.4.5.38.1.     Sales Forecast (USD Million)

14.4.5.38.2.     Net Present Value (USD Million)

14.4.5.38.3.     Value Creation Analysis

14.4.5.39.        CT103A (Nanjing IASO Biotherapeutics)

14.4.5.39.1.     Sales Forecast (USD Million)

14.4.5.39.2.     Net Present Value (USD Million)

14.4.5.39.3.     Value Creation Analysis

15. PROMOTIONAL ANALYSIS

15.1.                Chapter Overview

15.2.                Channels Used for Promotional Campaigns

15.3.                Summary of Product Website Analysis

15.4.                Summary of Patient Support Services and Informative Downloads

15.5.                Kymriah®: Promotional Analysis

15.5.1.             Drug Overview

15.5.2.             Product Website Analysis

15.5.2.1.          Message for Healthcare Professionals

15.5.2.2.          Message for Patients

15.5.2.3.          Informative Downloads

15.5.3.             Patient Support Services

15.6.                Yescarta®: Promotional Analysis

15.6.1.             Drug Overview

15.6.2.             Product Website Analysis

15.6.2.1.          Message for Healthcare Professionals

15.6.2.2.          Message for Patients

15.6.2.3.          Informative Downloads

15.6.3.             Patient Support Services

15.7.                Tecartus™: Promotional Analysis

15.7.1.             Drug Overview

15.7.2.             Product Website Analysis

15.7.2.1.          Message for Healthcare Professionals

15.7.2.2.          Message for Patients

15.7.2.3.          Informative Downloads

15.7.3.             Patient Support Services

15.8.                Breyanzi®: Promotional Analysis

15.8.1.             Drug Overview

15.8.2.             Product Website Analysis

15.8.2.1.          Message for Healthcare Professionals

15.8.2.2.          Message for Patients

15.8.2.3.          Informative Downloads

15.8.3.             Patient Support Services

15.9.                Abecma™: Promotional Analysis

15.9.1.             Drug Overview

15.9.2.             Product Website Analysis

15.9.2.1.          Message for Healthcare Professionals

15.9.2.2.          Message for Patients

15.9.2.3.          Informative Downloads

15.9.3.             Patient Support Services

15.10.              Carvykti™: Promotional Analysis

15.10.1.           Drug Overview

15.10.2.           Product Website Analysis

15.10.2.1.        Message for Healthcare Professionals

15.10.2.2.        Message for Patients

15.10.2.3.        Informative Downloads

15.10.3.           Patient Support Services

16. COMPANY PROFILES

16.1.                Chapter Overview

16.2.                Alaunos Therapeutics

16.3.                Autolus

16.4.                Bluebird Bio

16.5.                Bristol Myers Squibb

16.6.                Carsgen Therapeutics

16.7.                Cellectis

16.8.                Cellular Biomedicine Group

16.9.                Gilead Sciences

16.10.              Innovative Cellular Therapeutics

16.11.              Kuur Therapeutics

16.12.              Noile-Immune Biotech

16.13.              Novartis

16.14.              Shanghai GeneChem

16.15.              Sinobioway Cell Therapy

16.16.              Takara Bio

16.17.              Wellington Zhaotai Therapies

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

18.1.                Chapter Overview

18.2.                Glycostem Therapeutics

18.2.1.             Interview Transcript: Troels Jordansen, Chief Executive Officer

18.2.                Gracell Biotechnologies

18.2.1.             Interview Transcript: Wei (William) Cao, Chief Executive Officer

18.3.                TxCell

18.3.1.             Interview Transcript: Miguel Forte, Chief Operating Officer

18.4.                Kite Pharma

18.4.1.             Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

18.5.                Celyad

18.5.1.             Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys

18.6.                Waisman Biomanufacturing

18.6.1.             Interview Transcript: Brian Dattilo, Manager of Business Development

18.7.                Theravectys

18.7.1.             Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy Business Development

18.8.                Changhai Hospital

18.8.1.             Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

18.9.                University of Colorado

18.9.1.             Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/antiviral-drugs-market.html

You may also be interested in the following titles:

DNA Encoded Libraries

Quantum Computing in Drug Discovery Services Market

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com